BRPI0413869A - antagonistas modificados do receptor il-4 da muteìna - Google Patents

antagonistas modificados do receptor il-4 da muteìna

Info

Publication number
BRPI0413869A
BRPI0413869A BRPI0413869-4A BRPI0413869A BRPI0413869A BR PI0413869 A BRPI0413869 A BR PI0413869A BR PI0413869 A BRPI0413869 A BR PI0413869A BR PI0413869 A BRPI0413869 A BR PI0413869A
Authority
BR
Brazil
Prior art keywords
antagonists
modified
mutein
receptor
receptor antagonists
Prior art date
Application number
BRPI0413869-4A
Other languages
English (en)
Inventor
Clark Pan
Steve Roczniak
Jeffrey Michael Greve
Stephanie L Yung
Malinda Longphre
Teresa Mo-Fun Wong
Adrian Tomkinson
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BRPI0413869A publication Critical patent/BRPI0413869A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ANTAGONISTAS MODIFICADOS DO RECEPTOR IL-4 DA MUTEìNA". Esta invenção se refere a antagonistas modificados do receptor IL-14 da muteina que compreende um antagonista do receptor da muteína L14 acoplado a polietileno glicol. Tambem são providos formulações e dosagens e métodos relacionados para a administração dos mesmos para finalidades terapêuticas. Esses antagonistas modificados do receptor de IL-4, composições e métodos, proporcionam uma opção de tratamento para aqueles indivíduos que sofrem com um distúrbio respiratório tal como a asma através da inibição da hipercondição de resposta e da eosinofilia das vias respiratórias mediadas pelo IL-4 e IL-13. De modo mais especifico, esses antagonistas têm uma duração de efeito aumentada versus os antagonistas de IL-4 e IL-13 não modificados em virtude de uma maior meia-vida no plasma.
BRPI0413869-4A 2003-08-29 2004-07-20 antagonistas modificados do receptor il-4 da muteìna BRPI0413869A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49890603P 2003-08-29 2003-08-29
US52822803P 2003-12-09 2003-12-09
US53018203P 2003-12-17 2003-12-17
US10/820,559 US7404957B2 (en) 2003-08-29 2004-04-08 Modified IL-4 mutein receptor antagonists
PCT/US2004/023310 WO2005023860A2 (en) 2003-08-29 2004-07-20 Modified il-4 mutein receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0413869A true BRPI0413869A (pt) 2006-10-24

Family

ID=34280052

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413869-4A BRPI0413869A (pt) 2003-08-29 2004-07-20 antagonistas modificados do receptor il-4 da muteìna

Country Status (15)

Country Link
US (1) US7404957B2 (pt)
EP (1) EP1660529A2 (pt)
JP (1) JP4774368B2 (pt)
KR (1) KR20070008505A (pt)
AU (1) AU2004270638B2 (pt)
BR (1) BRPI0413869A (pt)
CA (1) CA2536586A1 (pt)
CZ (1) CZ2006206A3 (pt)
DK (1) DK200600449A (pt)
ES (1) ES2315146A1 (pt)
FI (1) FI20060188A7 (pt)
IL (1) IL173746A0 (pt)
IS (1) IS8315A (pt)
MX (1) MXPA06002285A (pt)
WO (1) WO2005023860A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785580B2 (en) * 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
DK1791555T3 (da) * 2004-09-10 2013-06-10 Pharmaorigin Aps Fremgangsmåde til behandling af lokal tracheal, bronchial eller alveolær blødning eller hæmoptyse
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
MX2008008968A (es) * 2006-01-11 2008-09-10 Aerovance Inc Metodos y composiciones para tratar asma en primates humanos y no humanos.
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2178547A4 (en) * 2007-07-11 2011-02-16 Aerovance Inc PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD
WO2010105227A1 (en) * 2009-03-13 2010-09-16 Aerovance, Inc. Methods of renaturation of recombinant proteins
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
WO2015000585A1 (en) 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
EP3553078A1 (en) * 2018-04-11 2019-10-16 Julius-Maximilians-Universität Würzburg Glyco-engineered interleukin-4 based antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US9303613B2 (en) 2012-02-24 2016-04-05 Ford Global Technologies, Llc Control of vehicle electrical loads during engine auto stop event

Also Published As

Publication number Publication date
WO2005023860A3 (en) 2005-06-23
DK200600449A (da) 2006-03-29
AU2004270638B2 (en) 2010-10-07
JP2007526757A (ja) 2007-09-20
US7404957B2 (en) 2008-07-29
CZ2006206A3 (cs) 2007-01-10
CA2536586A1 (en) 2005-03-17
ES2315146A1 (es) 2009-03-16
MXPA06002285A (es) 2007-03-15
IS8315A (is) 2006-02-20
AU2004270638A1 (en) 2005-03-17
IL173746A0 (en) 2006-07-05
AU2004270638A2 (en) 2005-03-17
FI20060188L (fi) 2006-02-24
EP1660529A2 (en) 2006-05-31
WO2005023860A2 (en) 2005-03-17
KR20070008505A (ko) 2007-01-17
JP4774368B2 (ja) 2011-09-14
FI20060188A7 (fi) 2006-04-28
US20050059590A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
BRPI0413869A (pt) antagonistas modificados do receptor il-4 da muteìna
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
NO20075354L (no) Forbindelser, isomerer og farmasoytiske akseptable salter derav, som vanilloidreseptorantagoniser, og farmasoytiske preparater inneholdende slike
BRPI0313764A2 (pt) método de preparação de composições de inalação de pó seco
WO2009065007A8 (en) Modified il-4 mutein receptor antagonists
FR2746101B1 (fr) Composes bicycliques-aromatiques
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
BR0215288A (pt) Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente
MXPA04010860A (es) Composiciones terapeuticas de 1,2,3,6-tetrahidropirimidin-2-ona y metodos para usarla.
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
IL168308A (en) Compositions containing roflumilast and formoterol
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE60321954D1 (de) Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CY1112389T1 (el) Συνθεση ξηρας κονεως που περιλαμβανει σωματιδια συν-αλεσης εκτοξευσης για πνευμονικη εισπνοη

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.